Healthcare
Coya Therapeutics Inc.(COYA)
Live Price
Offline$4.92
-2.19% today
1Y Change
-18.58%
Window
Jun 25, 2025 โ Jun 16, 2026
- Market Cap
- $70.00M
- Revenue Growth
- +123.6%
- EPS Growth
- -29.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Coya Therapeutics Inc. (COYA) is a Healthcare stock with a market cap of $70.00M and listed on NASDAQ. The stock last traded around $4.92 and down 18.6% across the available one-year price window (Jun 25, 2025 โ Jun 16, 2026). Baseline metrics include revenue growth of +123.6%, EPS growth of -29.6%, a dividend yield of 0.0%. What stands out right now is revenue +123.6%, EPS -29.6%, free cash flow -4.4% with operating margin -255.0% and ROIC -46.0%. Valuation already assumes a fairly strong business story at price/sales 8.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines COYA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+123.6% vs +7.6% peer median
Operating Margin
Below sector median
-255.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +123.6% and EPS is at -29.6%, with operating margin around -255.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -1.5% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +5.8% | +6.5% | +2.8% |
2026 Mar 16, 2026 | -24.8% | -2.2% | -6.2% | -0.9% |
2025 Nov 12, 2025 | -600.0% | -2.1% | -4.9% | +2.6% |
Benchmark Edge
COYA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
COYA
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
COYA Max Drawdown
-48.64%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for COYA and SPY.
Company Overview
Coya Therapeutics Inc.
NASDAQ
Coya Therapeutics Inc. is a biopharmaceutical company focused on the development of regenerative medicines to treat neurodegenerative and autoimmune diseases. Central to its mission is the advancement of innovative treatments that leverage immunotherapy and stem cell technology. The company's research and development efforts target conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders, aiming to provide therapeutic solutions where current options are limited. Coya Therapeutics is particularly noted for its emphasis on utilizing regulatory T-cells to modulate the immune system and potentially slow disease progression. This focus places Coya Therapeutics at the intersection of cutting-edge biotechnology and immunology, making it a noteworthy participant in the burgeoning biopharmaceutical sector. Its work is significant in the market as it addresses unmet medical needs, offering hope for transformative advancements in patient care in the face of complex and debilitating diseases.
- Leadership
- Dr. Arun Swaminathan Ph.D.
- Employees
- 8
- Street Address
- 5850 San Felipe St., Suite 500
- Mailing
- Houston, TX, 77057
- Region
- Houston, TX, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.9
- Price/Book
- 1.7
Growth
- Revenue
- +123.6%
- EPS
- -29.6%
- Free Cash Flow
- -4.4%
Profitability
- Gross Margin
- 99.7%
- Operating Margin
- -255.0%
- Net Margin
- -267.1%
- ROE
- -64.3%
- ROIC
- -46.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 8.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.